Oruka Therapeutics, Inc. (ORKA) - Q3 2024 Filing Summary
Business Context and Reporting Period
Oruka Therapeutics, Inc. is an early-stage biotechnology company focused on developing biologics for inflammatory skin diseases, specifically psoriasis. The reporting period covers the three months ended September 30, 2024, and the period from the company's inception on February 6, 2024, through September 30, 2024. The company was formed via a reverse recapitalization with ARCA biopharma, Inc., consummated on August 29, 2024, and subsequently effected a 1-for-12 reverse stock split on September 3, 2024.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2024 | Period from Inception (Feb 6) to Sept 30, 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(28.6) million | $(57.9) million |
| Operating Expenses | $(29.4) million | $(57.8) million |
| Research & Development (R&D) | $(25.7) million | $(49.6) million |
| General & Administrative (G&A) | $(3.8) million | $(8.2) million |
| Cash and Cash Equivalents (Sept 30, 2024) | $410.9 million | |
| Net Cash Used in Operating Activities | N/A | $(39.0) million |
| Net Cash Provided by Financing Activities | N/A | $450.1 million |
Material Changes and Capital Events
- Reverse Recapitalization: On August 29, 2024, the company completed a merger with ARCA biopharma, Inc., becoming a public entity. Pre-Merger Oruka was deemed the accounting acquirer.
- Pre-Closing Financing: Immediately prior to the merger, the company raised approximately $275.0 million in gross proceeds (including $25.0 million from a convertible note conversion).
- PIPE Financing: In September 2024, the company closed a PIPE financing raising approximately $188.7 million in net proceeds through the sale of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants.
- Stock Split: A 1-for-12 reverse stock split was effective September 3, 2024. All share data in this summary reflects the post-split basis.
- Related Party Transactions: A significant portion of R&D expenses ($13.5 million for the quarter) relates to agreements with Paragon Therapeutics, Inc. and Paruka Holding LLC.
Outlook, Risks, and Management Commentary
- Liquidity: Management expects the $410.9 million cash balance as of September 30, 2024, to be sufficient to fund operations for at least 12 months. The company anticipates continued significant losses as it advances clinical development.
- Pipeline Status:
- ORKA-001 (IL-23p19): Lead program for psoriasis. Phase 1 trial initiation expected in Q1 2025. Interim data expected in H2 2025.
- ORKA-002 (IL-17A/F): Co-lead program for psoriasis and psoriatic arthritis. Phase 1 trial initiation expected in Q3 2025.
- Risks: The company is preclinical with no approved products. Key risks include the failure of clinical trials, inability to raise additional capital, reliance on third-party manufacturers (including WuXi Biologics, subject to the proposed BIOSECURE Act), and potential patent challenges.
- Unusual Items: The financial statements include significant non-cash stock-based compensation ($9.0 million for the quarter), largely driven by the Paruka Warrant Obligation ($7.3 million).
Investor Verification Checklist
- Cash Runway: Verify the burn rate against the $410.9 million cash balance to confirm the 12-month liquidity assertion.
- Related Party Concentration: Assess the dependency on Paragon Therapeutics for R&D services and the valuation of the Paruka Warrant Obligation liability.
- Regulatory Risks: Review the potential impact of the BIOSECURE Act on the company's relationship with WuXi Biologics and other foreign CMOs.
- Capital Structure: Examine the terms of the Series A and Series B convertible preferred stock and the dilution potential of outstanding pre-funded warrants and options.
- Clinical Milestones: Monitor the timeline for the initiation of Phase 1 trials for ORKA-001 and ORKA-002 as announced.